Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03298984 · ClinicalTrials.gov registry record · Phase 1
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03298984 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 32 participants.
The verdict
NCT03298984, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this Phase I study is to determine the safety and tolerability including the maximum dose (MTD) and dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by cytarabine/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML
Interventions
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG Alvocidib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2020-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03298984
The ClinicalTrials.gov registry entry for NCT03298984 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT03298984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03298984 about?
NCT03298984 is a clinical study titled "Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).". The purpose of this Phase I study is to determine the safety and tolerability including the maximum dose (MTD) and dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by cytarabine/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed an...
What is the current status of trial NCT03298984?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-09-25. Estimated completion is 2020-03-20.
What interventions are being tested in trial NCT03298984?
The interventions under investigation include: Cytarabine (DRUG), Daunorubicin (DRUG), Alvocidib (DRUG).
Who is sponsoring clinical trial NCT03298984?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.